Viewing Study NCT00189761


Ignite Creation Date: 2025-12-24 @ 11:51 AM
Ignite Modification Date: 2025-12-30 @ 5:11 PM
Study NCT ID: NCT00189761
Status: COMPLETED
Last Update Posted: 2006-09-20
First Post: 2005-09-13
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients
Sponsor: Astellas Pharma Inc
Organization:

Study Overview

Official Title: A Phase 2, Open-Label, Multi-Center Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in De Novo Bone Marrow Transplant Recipients
Status: COMPLETED
Status Verified Date: 2006-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A study to assess efficacy, safety and pharmacokinetics of a tacrolimus new oral formulation (MR4) in de novo bone marrow transplant recipients
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: